Transient Immunomodulation Allows Repeated Injections of AAV1 and Correction of Muscular Dystrophy in Multiple Muscles
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Exon-skipping AAV1-U7-associated therapy is a promising treatment for Duchenne muscular dystrophy (DMD). We have shown earlier that the newly rescued dystrophin protein is stably expressed for months in mice and dogs, and does not induce immune rejection of transduced fibers. In this study, we used the dystrophic mdx mouse as a preclinical model to characterize the immune response to the adeno-associated virus 1 (AAV1) vector, and tested the feasibility of administering multiple AAV1 injections to extend the treatment to several muscles. We found that re-injections of AAV1 vector are compromised as early as 3 days after the first injection, coincident with a rapid increase in AAV1-specific immunoglobulin M (IgM) and IgG in the serum. Adoptive transfer of immune sera confirmed the rapid appearance of an AAV1 neutralization activity, and experiments with immunoglobulin-deficient (microKO) mice proved that antibodies (Abs) are the only effectors responsible for AAV1-U7 elimination. It is important to note, however, that the AAV2 vector still generated an adverse immune response in microKO mice. By blocking the T-B crosstalk with anti-CD40 Abs and CTLA4/Fc fusion protein, we found that a mere 5 days of immunomodulation treatment was sufficient to totally abrogate the formation of anti-AAV1 Abs and to allow for the correction of muscular dystrophy in multiple muscles, provided the treatment was administered during each challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies showed CD28/B7 and CD40/CD40L blockade resulted in mitigation of inflammatory response and allowed for vector re-administration [203–205].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [204]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Kitamura, D., Roes, J., Kühn, R., & Rajewsky, K. (1991) · Nature · doi:10.1038/350423a0 · Cited by 1,783
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Self-citationRutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Cited by
Progress toward Gene Therapy for Duchenne Muscular Dystrophy
Chamberlain, J. R., & Chamberlain, J. S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.019 · Cited by 224
“If immune responses against the vector can be avoided, such as with a transient immune suppression protocol, then readministration might be possible.(37,54,55)”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
Godfrey, C., Desviat, L. R., Smedsrød, B. H., Piétri‐Rouxel, F., Denti, M. A., Disterer, P., Lorain, S., Nogales‐Gadea, G., Sardone, V., Anwar, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607199 · Cited by 168
“The main limitation to this approach is that the immune response prevents repeated AAV treatment (Lorain et al, 2008).”
Self-citationMuscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping
Vulin, A., Barthélémy, I., Goyenvalle, A., Thibaud, J. L., Beley, C., Griffith, G., Benchaouir, R., Hir, M. L., Unterfinger, Y., Lorain, S., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.181 · Cited by 161
Self-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
The Status of Exon Skipping as a Therapeutic Approach to Duchenne Muscular Dystrophy
Lu, Q., Yokota, T., Takeda, S., García, L., Muntoni, F., & Partridge, T. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.219 · Cited by 111
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle
Hoffman, E. P., Bronson, A., Levin, A. A., Takeda, S., Yokota, T., Baudy, A. R., & Connor, E. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.050 · Cited by 119
“viral gene therapy; as previously noted, gene therapy of DMD has faced persistent hurdles of immune response, viral production, and systemic delivery.(47)”
MethodThe potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“AAV1 A1ATD [161], DMD [36,154] Hemophilia B [96], LGMD2D [162], LPLD [163], XLMTM [197], Pompe disease [19] AAV2 A1ATD [169], DMD [164], McArdle disease [198] AAV6 Hemophilia B [104] AAV7 DMD [173,178], Pompe disease [172] AAV8 Heart failure [176] AAV9 Hemophilia B [185] DMD [189] CMD [192] t.”
InfluentialSalmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
AAV Genome Loss From Dystrophic Mouse Muscles During AAV-U7 snRNA-mediated Exon-skipping Therapy
Le Hir, M., Goyenvalle, A., Peccate, C., Précigout, G., Davies, K. E., Voit, T., Garcia, L., & Lorain, S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.121 · Cited by 80
Self-citationLong-Term Benefit of Adeno-Associated Virus/Antisense-Mediated Exon Skipping in Dystrophic Mice
Denti, M. A., Incitti, T., Sthandier, O., Nicoletti, C., Angelis, F. G. D., Rizzuto, E., Auricchio, A., Musarò, A., & Bozzoni, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.012 · Cited by 68
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
Self-citationHuman Galectin 3 Binding Protein Interacts with Recombinant Adeno-Associated Virus Type 6
Denard, J., Beley, C., Kotin, R., Lai-Kuen, R., Blot, S., Leh, H., Asokan, A., Samulski, R. J., Moullier, P., Voit, T., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00297-12 · Cited by 64
“Acquired immunity and neutralizing antibodies present in a large fraction of the human population might obviously be restrictive for rAAV gene delivery (5, 20, 27, 29, 30).”
BackgroundGene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“However, the ability to block cellular and humoral immunity sufficiently to allow vector readministration years after the initial treatment may require blockade of CD4 and/or CD8 T-cell recognition of vector and transgene, and might be aided by activation of T-regulatory cells or by direct induction of tolerance again…”
BackgroundMyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59
Self-citationImpending therapies for Duchenne muscular dystrophy
Partridge, T. A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834aa3f1 · Cited by 58
Harbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R. (2012) · Journal of General Virology · doi:10.1099/vir.0.035113-0 · Cited by 54
“Concurrent immunosuppressant (e.g. cyclosporin) administration or plasmapheresis along with the AAV vector may also temporarily reduce immune responses to the virus capsid and/or transgene (Lorain et al., 2008; Monteilhet et al., 2011).”
BackgroundThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis
Tosolini, A. P., & Sleigh, J. N. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00405 · Cited by 52
“Moreover, AAV9 displays neuronal tropism and can mediate stable, long-term expression with a single administration, which is important given immunogenicity issues associated with viruses (Lorain et al., 2008).”
BackgroundAntisense pre-treatment increases gene therapy efficacy in dystrophic muscles
Peccate, C., Mollard, A., Hir, M. L., Julien, L., McClorey, G., Jarmin, S., Heron, A. L., Dickson, G., Benkhelifa‐Ziyyat, S., Piétri‐Rouxel, F., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw201 · Cited by 49
“In the context of an AAV-U7 clinical trial for DMD, AAV genome fate in dystrophic muscles is of major importance since the vector capsid immunogenicity currently limits repeated treatment (21).”
Self-citationCryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
Sen, D., Balakrishnan, B., Gabriel, N., Agrawal, P., Roshini, V., Samuel, R., Srivastava, A., & Jayandharan, G. R. (2013) · Scientific Reports · doi:10.1038/srep01832 · Cited by 44
Lorain, S., Peccate, C., Hir, M. L., Griffith, G., Philippi, S., Précigout, G., Mamchaoui, K., Jollet, A., Voït, T., & García, L. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt621 · Cited by 45
“Adeno-associated virus (AAV)2/1 vectors were generated using a three-plasmid transfection protocol as described (30).”
MethodSelf-citationIncitti, T., Angelis, F. G. D., Cazzella, V., Sthandier, O., Pinnarò, C., Legnini, I., & Bozzoni, I. (2010) · Molecular Therapy · doi:10.1038/mt.2010.123 · Cited by 47
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“Plasmapheresis and transient immunosuppression (anti-CD40 Ab, CTLA-4 Ig, highdose corticosteroids, rapamycin, rituximab, or combinations of these treatments) are currently being tested to allow for repeat injections (NCT02240407) (76, 113, 181).”
BackgroundHoogaars, W. M. H., Mouisel, É., Pasternack, A. H., Hulmi, J. J., Relizani, K., Schuelke, M., Schirwis, E., García, L., Ritvos, O., Ferry, A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.056 · Cited by 43
“However, AAV-1 capsid, which was used in our study, causes a humoral immune response against the AAV-1 itself, which makes subsequent injection inefficient, but no cytotoxic T-cell response (Lorain et al. , 2008).”
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy
Azibani, F., Brull, A., Arandel, L., Beuvin, M., Nelson, I. P., Jollet, A., Ziat, E., Prudhon, B., Benkhelifa‐Ziyyat, S., Bitoun, M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.12.012 · Cited by 40
“Adeno-associated virus (AAV2/9) vectors were generated using a three-plasmid transfection protocol as described previously.(15,41) Virus titers measured by qPCR ranged from 7.”
MethodSelf-citationOkada, T., & Takeda, S. (2013) · Pharmaceuticals · doi:10.3390/ph6070813 · Cited by 45
“To establish the feasibility of multiple AAV1 injections for extending the treatment to whole body muscles, the dystrophic mdx mouse was repeatedly transduced with AAV1 vector, and the immune response was characterized [86].”
Mendoza, S. D., El-Shamayleh, Y., & Horwitz, G. D. (2017) · Journal of Neurophysiology · doi:10.1152/jn.00780.2016 · Cited by 41
“Other strategies to overcome the anti-AAV immune response include immunosuppression and plasmapheresis (Lorain et al. 2008; Mingozzi and High 2013; Monteilhet et al. 2011), but these may have adverse consequences for monkeys prepared for chronic neurophysiological recordings.”
BackgroundD’Amario, D., Gowran, A., Canonico, F., Castiglioni, E., Rovina, D., Santoro, R., Spinelli, P., Adorisio, R., Amodeo, A., Perrucci, G. L., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090291 · Cited by 36
Selot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“These data were further confirmed by use of MR1, the anti CD40 ligand antibody to block the T and B cell cross talk in dystrophic mdx mouse model of muscular dystrophy [69].”
Adriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., & Boyer, O. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00199 · Cited by 22
“Indeed, there has been experimental evidence that CTLA-4/Ig in combination with a monoclonal antibody to CD40L (MR1) in the context of gene therapy can block immune responses and allow vector readministration in the mouse (Halbert et al., 1998; Lorain et al., 2008) .”
BackgroundCarpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcia, L., Davoust, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25
Self-citationDystrophic Cardiomyopathy—Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies
Johnstone, V., Viola, H. M., & Hool, L. C. (2017) · Genes · doi:10.3390/genes8040108 · Cited by 28
“In addition, repeat administration is likely to be problematic due to the presence of neutralising antibodies as a consequence of the first administration [139].”
BackgroundPhilippi, S., Lorain, S., Beley, C., Peccate, C., Précigout, G., Spuler, S., & García, L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv141 · Cited by 28
“Recombinant adeno-associated viruses (rAAV2/1) known for their high muscle tropism (47,48) were produced expressing mPTM 31.”
MethodSelf-citationForand, A., Muchir, A., Mougenot, N., Sévoz‐Couche, C., Peccate, C., Lemaître, M., Izabelle, C., Wood, M. J. A., Lorain, S., & Piétri‐Rouxel, F. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.011 · Cited by 25
Self-citationExploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties
Gao, G., Li, Z., & Danos, O. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_4 · Cited by 28
Self-citationGene and splicing therapies for neuromuscular diseases
Goyenvalle, A. (2015) · Frontiers in bioscience · doi:10.2741/4367 · Cited by 27
“In the same way, blocking the T-B crosstalk with anti-CD40 antibodies and CTLA4/ Fc fusion protein was sufficient to totally abrogate the formation of anti-AAV antibodies and to allow for the correction of muscular dystrophy in multiple muscles of mdx mice model after AAV re-administration (113).”
BackgroundSelf-citationChen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
“showed that multiple intramuscular administration was possible for AAV serotype 1 and, to a lesser degree, serotype 2 in μMT mice [63].”
BackgroundMorgan, J. E., & Muntoni, F. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210683 · Cited by 19
“But a major limitation to AAV-mediated gene therapy is that AAV induces an immune response, which makes re-administration a challenge [38, 39].”
BackgroundOptimization of trans-Splicing for Huntington's Disease RNA Therapy
Rindt, H., Tom, C. M., Lorson, C. L., & Mattis, V. B. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00544 · Cited by 18
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery
Jackson, C. B., Richard, A. S., Ojha, A., Conkright, K. A., Trimarchi, J. M., Bailey, C. C., Alpert, M. D., Kay, M. A., Farzan, M., & Choe, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.004 · Cited by 19
Zhong, C., Jiang, W., Wang, Y., Sun, J., Wu, X., Zhuang, Y., & Xiao, X. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.129 · Cited by 17
“21 Frentsch et al. demonstrated that CTLA4-Ig enabled redosing of AAV8 vectors by blocking NAbs and improved AAV-mediated factor IX (FIX) expression in C57BL/6J mice.”
Saito, S., Nakamura, Y., Miyashita, S., Sato, T., Hoshina, K., Okada, M., Hasegawa, H., Oishi, M., Fujii, Y., Körbelin, J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179729 · Cited by 13
Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies
Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y. (2014) · BioMed Research International · doi:10.1155/2014/818107 · Cited by 12
“To guarantee a relevant restoration of muscle function in DMD patients, it is necessary to perform repetitive AAV infusions to target multiple muscular territories.”
BackgroundIn vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model
Gopalappa, R., Lee, M., Kim, G., Jung, E. S., Lee, H., Hwang, H.-Y., Lee, J. G., Kim, S. J., Yoo, H. J., Sung, Y. H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.027 · Cited by 8
Hasyim, A. A., Iyori, M., Mizuno, T., Abe, Y.-I., Yamagoshi, I., Yusuf, Y., Syafira, I., Shahnaij, M., Sakamoto, A., Yamamoto, Y., et al. (2022) · Parasitology International · doi:10.1016/j.parint.2022.102652 · Cited by 7
“AAV1 provides high levels of transgene expression in the muscle cells [18-20].”
Efficient AAV Vector Production System: Towards Gene Therapy For Duchenne Muscular Dystrophy
Okada, T. (2013) · InTech eBooks · doi:10.5772/53023 · Cited by 7
“[58] To establish the feasibility of multiple AAV1 injections for extending the treat‐ ment to whole body muscles, the dystrophic mdx mouse was repeatedly transduced with AAV1 vector, and the immune response was characterized.[59] By blocking the T-B crosstalk with anti-CD40 Abs and CTLA4/Fc fusion protein, a five-day…”
MethodMolecular Therapies for Muscular Dystrophies
Lin, A. Y., & Wang, L. H. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0509-2 · Cited by 7
Cell-Based Therapy for Spinal Muscular Atrophy
Han, F., Ebrahimi‐Barough, S., Abolghasemi, R., Ai, J., & Liu, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4370-8_8 · Cited by 4
Xicluna, R., Yamada, K., Gonzalez-Visiedo, M., Greenwood, C. M., Zaugg, D., Waiz, D., Steiner, G., Hahn, K., Schwandt, T., Otteneder, M. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.014 · Cited by 2
Evaluating Readministration of Adeno-Associated Virus for Gene Therapy
Arjomandnejad, M., & Keeler, A. M. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29204.mar · Cited by 2
AAV-Mediated Exon Skipping for Duchenne Muscular Dystrophy
Benchaouir, R., & Goyenvalle, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_20 · Cited by 1
Self-citationOptimization of exon skipping therapy for the treatment of Duchenne muscular dystrophy
Bizot, F. (2023) · theses.fr (ABES) · doi:10.70675/ddfe7d49zf3a2z4c89za617z7673da520988 · Cited by 1
Vicidomini, A. (2024) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00097257
Carpentier, M. (2013) · theses.fr (ABES) · doi:10.70675/fa69ca30zf46az45f1z9638z003bd41555e4
RNA-based therapies for dysferlinopathies
Philippi, S. (2014) · theses.fr (ABES) · doi:10.70675/36df5bbcz5825z4793za0f5zd1f36e3ab980
“…immune response has been detected to act against the AAV2 capsid after injection into murine muscle, but not against the AAV1 capsid that lack the VP3 heparan sulfate proteoglycan–binding motif identified immunogenic in the AAV2 capsid in mice (Vandenberghe et al., 2006; Lorain et al., 2008).”
BackgroundPetkova, M. V. (2016) · theses.fr (ABES) · doi:10.70675/c9ccc0a7z00b1z4264zb141zca90e3bd5543
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Promises of co-stimulatory inhibition for durable and repeatable AAV gene therapy
Kuranda, K., Gross, D., & Ronzitti, G. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.014
Self-citation
Metadata
- Authors
- Lorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L.
- Affiliations
- Inserm (FR)
- Hôpital Necker-Enfants Malades (FR)
- University of Oxford (GB)
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 541-547
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2005245653
- Cited by
- 62
- References
- 46
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 4
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Duchenne Parent Project
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, AAV1, exon skipping, mdx mice, adoptive transfer, AAV2, immunomodulation, gene therapy
- MeSH terms
- Abatacept, Dependovirus, Animals, Antibody Formation, Fluorescent Antibody Technique, Genetic Vectors, Immunoglobulin G, Immunoglobulin M, Immunoglobulins, Mice, Inbred C57BL, Transduction, Genetic, Genetic Therapy, Immunoconjugates, CD40 Antigens, Muscular Dystrophy, Duchenne, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.